Published in Nephrol Dial Transplant on September 18, 2008
Biosimilars: Implications for health-system pharmacists. Am J Health Syst Pharm (2013) 1.36
Interchangeability, immunogenicity and biosimilars. Nat Biotechnol (2012) 1.28
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica (2011) 1.25
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden. Biol Ther (2013) 1.03
Anemia in children with chronic kidney disease. Nat Rev Nephrol (2011) 0.97
Strategies for the profiling, characterisation and detailed structural analysis of N-linked oligosaccharides. Glycoconj J (2012) 0.88
Potential impact of subsequent entry biologics in nephrology practice in Canada. Can J Kidney Health Dis (2014) 0.85
A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia. Eur J Clin Pharmacol (2012) 0.84
Pure red cell aplasia after treatment of renal anaemia with epoetin theta. Clin Kidney J (2013) 0.80
Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects. MAbs (2012) 0.78
Switching Between Epoetins: A Practice in Support of Biosimilar Use. BioDrugs (2016) 0.77
Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol (2013) 0.76
Biosimilar epoetins. Nephrol Dial Transplant (2009) 0.75
Biosimilars and biopharmaceuticals: what the nephrologist needs to know--a position paper by the ERA-EDTA Council. Nephrol Dial Transplant (2009) 0.75
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med (2011) 6.34
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int (2002) 4.29
Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant (2004) 4.27
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int (2010) 3.53
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int (2014) 3.40
Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 3.17
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol (2007) 3.06
Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet (2004) 2.82
QUality European STudies (QUEST)--a step forward in the quality of RRT care. Nephrol Dial Transplant (2005) 2.73
Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int (2003) 2.69
PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med (2011) 2.64
Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol (2008) 2.64
Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol (2008) 2.44
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis (2002) 2.41
Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant (2008) 2.41
Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int (2008) 2.38
Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol (2006) 2.27
Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis (2002) 2.25
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant (2008) 2.24
Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 2.21
Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol (2007) 2.19
Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis (2003) 2.17
Detection of pulmonary congestion by chest ultrasound in dialysis patients. JACC Cardiovasc Imaging (2010) 2.16
Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol (2010) 2.15
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Management of atrial fibrillation in chronic kidney disease: double trouble. Am Heart J (2013) 2.14
Electrocardiographic P-wave characteristics in patients with end-stage renal disease: P-index and interatrial block. Int Urol Nephrol (2012) 2.12
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant (2003) 2.10
Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis (2006) 2.09
Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr (2007) 2.07
Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant (2002) 2.05
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl (2003) 2.04
COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. N Engl J Med (2007) 2.02
The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis (2006) 2.01
[In Process Citation]. Lakartidningen (2015) 2.01
Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med (2013) 2.00
Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol (2005) 1.99
When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant (2013) 1.95
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol (2013) 1.94
Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant (2007) 1.91
Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrol Dial Transplant (2010) 1.90
J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis (2006) 1.88
CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol (2009) 1.88
Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators. Nephrol Dial Transplant (2013) 1.88
A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant (2002) 1.86
Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol (2009) 1.86
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr (2013) 1.85
The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter. Nephrol Dial Transplant (2002) 1.82
Association between high ultrafiltration rates and mortality in uraemic patients on regular haemodialysis. A 5-year prospective observational multicentre study. Nephrol Dial Transplant (2007) 1.82
Inflammation in end-stage renal disease--what have we learned in 10 years? Semin Dial (2010) 1.82
Vascular calcification in chronic kidney disease. Am J Kidney Dis (2004) 1.81
FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int (2010) 1.81
Serum albumin as predictor of nutritional status in patients with ESRD. Clin J Am Soc Nephrol (2012) 1.80
Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant (2012) 1.80
Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int (2005) 1.80
Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int (2006) 1.80
The effect of joint exposures: examining the presence of interaction. Kidney Int (2009) 1.78
Fistula maturation: doesn't time matter at all? Nephrol Dial Transplant (2005) 1.77
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol (2008) 1.76
Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant (2006) 1.74
Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int (2004) 1.72
ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol (2011) 1.70
A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl (2003) 1.69
Recurrent membranous nephropathy in an allograft caused by IgG3κ targeting the PLA2 receptor. J Am Soc Nephrol (2012) 1.69
A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol (2007) 1.66
Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol (2005) 1.65
The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant (2006) 1.65
Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant (2010) 1.65
Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.65
Predicting mortality in haemodialysis patients: a comparison between lung ultrasonography, bioimpedance data and echocardiography parameters. Nephrol Dial Transplant (2013) 1.62
The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant (2004) 1.62
Ultrafiltration intensification in hemodialysis patients improves hypertension but increases AV fistula complications and cardiovascular events. J Nephrol (2011) 1.62
Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2012) 1.61
Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. Am J Kidney Dis (2004) 1.60
Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? Nephrol Dial Transplant (2004) 1.59
Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis (2005) 1.57
Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab (2014) 1.57
Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol (2008) 1.56
Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int (2008) 1.56
Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial. Am J Kidney Dis (2011) 1.55
Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. Am J Clin Nutr (2007) 1.55
Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens (2003) 1.55
Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. Am J Kidney Dis (2009) 1.54
Pulmonary hypertension in peritoneal dialysis patients: prevalence and risk factors. Perit Dial Int (2009) 1.54